Recent studies have converged on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and DA signaling. While GLP activators are increasingly employed for addressing type 2 diabetes, their unexpected effects on reward circuits, specifically influenced by dopaminergic networks, are gaining considerab… Read More